SK Bioscience renews vaccine control CEPI

CEO Ahn Jae-yong (Right) and Rich Hatchett, CEO of the Faction for Epidemic Preparedness Developments. (SK Bioscience)

South Korean drugmaker SK Bioscience announced Wednesday the company enjoys updated its capacity booking contract with the Coalition to Epidemic Preparedness Innovations.

Under the new agreement, CEPI can use part of SK Bioscience’s Andong production facility till 2022 for manufacturing COVID-19 vaccines.

SK Bioscience’s factory all over Andong, North Gyeongsang State, currently has a total along with nine production lines that’ll produce drug substances to make COVID-19 vaccines. Of the entirety, three will be reserved for CEPI, the Korean firm spoken.

SK Bioscience CEO Ahn Jae-yong and CEPI CEO Rich Hatchett met in Brussels to extend the contract, film due to expire by the end about the year.

In August last year, Novavax fixed a contract manufacturing deal with SK Bioscience, becoming the first shot developer to use the production capability reserved by CEPI.

Meanwhile, SK Bioscience CEO Ahn said nachi plans to produce its own COVID-19 vaccine at the Andong potager next year, aiming to step up really global vaccine production switch.

Unorthodox racing is currently in talks through foreign drug firms so that you sign additional contract processing deals, it said, using the latest agreement with CEPI.

CEPI is one of several members that lead all COVID-19 Vaccines Global Approach facility. CEPI also holds up development of COVID-19 vaccines helping to supply them through COVAX, a worldwide effort for equitable access to the vaccines.

By Shim Woo-hyun ( ws@heraldcorp. com )

SK Bioscience renews vaccine control CEPI
Philippines Truth